Crossmark

Opportunities for use of neuroimaging in de-risking drug development and improving clinical outcomes in psychiatry: an industry perspective

Published Online: 2024-08-21

Published Print: 2024-11

Authors

Etkin, Amit http://orcid.org/0000-0001-8259-3521
Powell, Jessica

Savitz, Adam J.
Funding

Funding for this research was provided by:

U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (DP1 MH116506, R44 MH123373)

U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
License Information

Text and Data Mining valid from 2024-08-21

Version of Record valid from 2024-08-21
More Information

Article History

Received: 25 March 2024

Revised: 30 May 2024

Accepted: 14 August 2024

First Online: 21 August 2024

Competing interests

: All authors receive salary and equity from Alto Neuroscience, Inc. AE holds equity from Akili Interactive and AJS holds equity from Johnson and Johnson.

Document is current